Flatiron Health has introduced six new artificial intelligence-driven, longitudinal hematology datasets aimed at supporting the requirements of researchers engaged in blood cancers, such as five groups of B-cell lymphomas and multiple myeloma. The datasets are based on over 505,000 patients with hematologic malignancies, facilitated through large-language-model-enabled data extraction and strict validation protocols. The company said that the new “Panoramic” data assets expand its real-world evidence platform into hematology, providing rich patient-level longitudinal data formerly aggregated in solid tumours. Using this large dataset, Flatiron intends to equip biopharma and academic researchers with treatment patterns, outcomes and real-world disease progression insights in blood cancers categories previously underrepresented in real-world data solutions. In a quote from an interview, a Flatiron spokesperson said: “Our AI-driven methodology has unlocked previously unimaginable depth in hematology data to enable longitudinal insights along patient journeys in B-cell lymphomas and multiple myeloma.”
Also Read: IntelePeer Launches SmartAnalytics Starter Pack to Enhance AI Integration in Healthcare Operations
These expansions are a complement to Flatiron’s more general mission of constructing extensive real-world evidence ecosystems throughout oncology. With the hematology modules live, customers are provided with de-identified clinical information which comprises diagnosis, treatment, outcomes and temporal evolution, optimized for research and drug development use-cases. Flatiron underscores that the datasets have been through robust quality assurance and validation in order to ensure they meet the requirements of regulated research use-cases. The company adds that the expansion is due to increasing demand from stakeholders to move beyond solid tumour datasets into hematologic malignancies, which tend to be complex in terms of data capture and longitudinal follow-up. As part of its strategic plan, Flatiron thinks that expansion into hematology will bring about faster discovery, enable regulatory science and create new opportunities in real-world evidence for rare and difficult to treat blood cancers as well.